Cargando…

α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis

BACKGROUND AND AIMS: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Filip, Rafał, Goliat, Błażej, Dziechciaż, Małgorzata, Dąbrowski, Piotr, Osuchowski, Michał, Paluszkiewicz, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501135/
https://www.ncbi.nlm.nih.gov/pubmed/31143480
http://dx.doi.org/10.1155/2019/2091089
_version_ 1783416059505672192
author Filip, Rafał
Goliat, Błażej
Dziechciaż, Małgorzata
Dąbrowski, Piotr
Osuchowski, Michał
Paluszkiewicz, Piotr
author_facet Filip, Rafał
Goliat, Błażej
Dziechciaż, Małgorzata
Dąbrowski, Piotr
Osuchowski, Michał
Paluszkiewicz, Piotr
author_sort Filip, Rafał
collection PubMed
description BACKGROUND AND AIMS: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of diseases of the small intestine, but an association with colectomy due to UC is very likely. METHODS AND RESULTS: We describe the case of a patient with a probable diagnosis of pan-UC accompanied by Sjögren's syndrome and partial IgA deficiency, who developed enteritis after a restorative pancolectomy. For induction and maintenance of remission, the patient was successfully treated with mycofenolate mofetil (MMF) and vedolizumab (VDZ). CONCLUSIONS: We suggest that a previously refractory to standard therapy UC-related enteritis can be treated with combination MMF and VDZ.
format Online
Article
Text
id pubmed-6501135
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65011352019-05-29 α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis Filip, Rafał Goliat, Błażej Dziechciaż, Małgorzata Dąbrowski, Piotr Osuchowski, Michał Paluszkiewicz, Piotr Case Rep Gastrointest Med Case Report BACKGROUND AND AIMS: Ulcerative colitis (UC) is a superficial diffuse inflammation restricted to the colon and rectum. Inflammation within the small bowel may occur several years after a pancolectomy. The pathogenesis is unknown and seems to be different from Crohn's disease or other causes of diseases of the small intestine, but an association with colectomy due to UC is very likely. METHODS AND RESULTS: We describe the case of a patient with a probable diagnosis of pan-UC accompanied by Sjögren's syndrome and partial IgA deficiency, who developed enteritis after a restorative pancolectomy. For induction and maintenance of remission, the patient was successfully treated with mycofenolate mofetil (MMF) and vedolizumab (VDZ). CONCLUSIONS: We suggest that a previously refractory to standard therapy UC-related enteritis can be treated with combination MMF and VDZ. Hindawi 2019-04-22 /pmc/articles/PMC6501135/ /pubmed/31143480 http://dx.doi.org/10.1155/2019/2091089 Text en Copyright © 2019 Rafał Filip et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Filip, Rafał
Goliat, Błażej
Dziechciaż, Małgorzata
Dąbrowski, Piotr
Osuchowski, Michał
Paluszkiewicz, Piotr
α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
title α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
title_full α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
title_fullStr α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
title_full_unstemmed α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
title_short α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
title_sort α4β7 integrin antagonist vedolizumab for the treatment of refractory ileitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501135/
https://www.ncbi.nlm.nih.gov/pubmed/31143480
http://dx.doi.org/10.1155/2019/2091089
work_keys_str_mv AT filiprafał a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis
AT goliatbłazej a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis
AT dziechciazmałgorzata a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis
AT dabrowskipiotr a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis
AT osuchowskimichał a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis
AT paluszkiewiczpiotr a4b7integrinantagonistvedolizumabforthetreatmentofrefractoryileitis